Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment

1 Jun 2020

Abstract excerpt

Dear Editor, Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), or programmed cell death protein 1 (PD-1) and its ligand (PD-L1) interaction achieve a significant improvement in overall survival (OS) and revolutionize treatment paradigms in many types of cancers.1, 2 Despite of the durable antitumor effect, ICIs could only benefit a minority of patients (∼20%) without...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Immunotherapy and Biomarkers
Share to Cancer Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32564494
DOI: 10.1002/ctm2.109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatmentPMID 32564494Read ↗

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.Semantic proximity Read ↗

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.Semantic proximity Read ↗

Telomere Maintenance Mechanisms in CancerSemantic proximity Read ↗

Telomerase and CD4 T Cell Immunity in CancerSemantic proximity Read ↗

Telomere maintaining germline and somatic variants in thyroid cancer and melanomaSemantic proximity Read ↗

Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome ProfilingSemantic proximity Read ↗

TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.Semantic proximity Read ↗

Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer.Semantic proximity Read ↗

Genomic footprints of activated telomere maintenance mechanisms in cancer.Semantic proximity Read ↗

Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.Semantic proximity Read ↗

High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma.Semantic proximity Read ↗

Thyroid carcinoma‐featured telomerase activation and telomere maintenance: Biology and translational/clinical significanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.